Systemic metabolic pathways in cancer cells reveal structural vulnerabilities: Rethinking therapeutic resistance through protein interactions

Indigenous healing traditions universally frame cancer as a symptom of systemic disharmony, whether in the balance of *qi* (TCM), *doshas* (Ayurveda), or *Country* (Indigenous Australian epistemologies). These systems emphasize metabolic resilience through diet, spiritual practice, and community support, offering low-cost, scalable alternatives to pharmaceutical interventions. However, such knowledge is systematically excluded from Western research agendas, which prioritize patentable molecular targets over holistic, preventive care. The erasure of these traditions reflects a colonial epistemological violence that equates complexity with primitivism.

The study’s focus on protein interactions mirrors mid-20th-century reductionist paradigms that isolated single genes or molecules as 'causes' of disease, ignoring the systemic failures of chemotherapy and radiation that emerged from these approaches. Historical precedents like the Tuskegee Syphilis Study reveal how racialized medical experimentation has shaped modern oncology, with Black patients disproportionately subjected to toxic treatments due to systemic neglect. The rise of targeted therapies in the 1990s paralleled the neoliberalization of healthcare, where personalized medicine became a luxury commodity rather than a public good.

Cross-culturally, cancer is rarely framed as a localized cellular defect but as a disruption of broader ecological or spiritual systems. In African traditional medicine, cancer is often treated with plants like *Sutherlandia frutescens*, which modulate inflammation and oxidative stress—mechanisms now recognized in Western science but dismissed when framed as 'alternative.' Similarly, Amazonian shamans use *ayahuasca* to address emotional and spiritual root causes of disease, with emerging evidence suggesting its role in modulating the gut-brain axis. These traditions highlight how metabolic resilience is tied to environmental and social harmony, a perspective absent in the original narrative.

The study’s focus on protein interactions aligns with modern systems biology, which recognizes that cancer cells adapt metabolically to survive therapeutic stress through pathways like autophagy and mitochondrial reprogramming. However, the research overlooks the role of the tumor microenvironment—comprising immune cells, fibroblasts, and extracellular matrix—in driving resistance, a gap that reflects the historical bias toward tumor-centric models. Emerging evidence also links metabolic reprogramming to chronic inflammation, a systemic condition influenced by diet, pollution, and socioeconomic stress, which the study does not address. The scientific framing thus remains constrained by disciplinary silos and funding priorities.

Artistic and spiritual traditions often depict cancer as a metaphor for societal decay or unprocessed trauma, as seen in Frida Kahlo’s self-portraits or the Yoruba concept of *aje* (a spiritual affliction requiring communal healing). These frameworks suggest that resistance to treatment may reflect deeper, unaddressed collective wounds, such as environmental degradation or intergenerational trauma. Creative arts therapies, like music or dance, have been shown to reduce stress and improve immune function in cancer patients, yet these modalities are rarely integrated into standard oncology care. The original narrative’s silence on these dimensions reflects a broader cultural dissociation between body, mind, and spirit.

Future-proofing cancer care requires modeling therapeutic resistance as a dynamic, adaptive system influenced by ecological, socioeconomic, and technological factors. Scenario planning should explore how industrial food systems, climate change, and AI-driven diagnostics could reshape cancer metabolism, with resistance emerging as a predictable outcome of unsustainable growth paradigms. Policymakers must anticipate the unintended consequences of precision medicine, such as the exacerbation of global health inequities if treatments remain unaffordable. Integrating Indigenous knowledge into future models could unlock low-cost, scalable interventions that address root causes rather than symptoms.

Marginalized communities—particularly Black, Indigenous, and low-income populations—experience higher cancer mortality rates due to structural barriers in healthcare access, environmental racism, and historical medical exploitation. Their lived experiences of cancer as a systemic injustice are rarely centered in research, which prioritizes lab-based discoveries over community-driven solutions. For example, the high prevalence of aggressive breast cancer in African American women is linked to socioeconomic stress and exposure to endocrine disruptors, yet these factors are sidelined in favor of genetic explanations. Amplifying these voices could reveal that resistance is not just a biochemical challenge but a symptom of broader societal failures.